Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | PEPD | P12955 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KIF11 | P52732 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062623 | 0.83 | PEPD (0.80) | MAPTNPC1RAB9APEPDMEN1 | |
| SCHEMBL6931409 | 0.83 | MAPT (0.56) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| SCHEMBL1880013 | 0.83 | RAB9A (0.57) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| Benzenesulfonamide SCHEMBL28177870 | 0.82 | CA1 (0.68) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| SCHEMBL14047972 | 0.82 | PEPD (0.64) | MAPTNPC1SMN1; SMN2RAB9APEPD | |
| SCHEMBL11925383 | 0.82 | SMN1; SMN2 (0.67) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| SCHEMBL3633396 | 0.82 | NPC1 (0.84) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| SCHEMBL474757 | 0.82 | ALDH1A1 (0.70) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| SCHEMBL10456830 | 0.80 | PEPD (0.52) | MAPTNPC1PEPDMEN1KMT2A | |
| SCHEMBL10456829 | 0.80 | PEPD (0.52) | MAPTNPC1PEPDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103221388-A | Novel sulfonamide compounds for inhibition of metastatic tumor growth | METASIGNAL THERAPEUTICS INC | 2013-07-24 | — | — | CN | claimed |
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| WO-2022003712-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-01-06 | — | — | WO | disclosed |
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| EP-3075726-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2016-10-05 | — | — | EP | disclosed |
| CN-103221388-B | For the novel sulfonamide compounds suppressing metastatic tumo(u)r to grow | 维理生物技术公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-102800816-B | There is the OLED device of fluoranthene electron transport materials | GLOBAL OLED TECHNOLOGY LLC (US) | 2016-05-18 | — | — | CN | disclosed |
| CN-1304060-A | Photographic component, compound and its preparing method | EASTMAN KODAK CO (US) | 2001-07-18 | — | — | CN | disclosed |
| CN-1288176-A | Tensile strength and durable fibrous photosensitive base materials | EASTMAN KODAK CO (US) | 2001-03-21 | — | — | CN | disclosed |
| CN-1284660-A | Flexible imaging element using microporous polyester piece | EASTMAN KODAK CO (US) | 2001-02-21 | — | — | CN | disclosed |
| CN-1260514-A | Colour photography element comprising compound for increasing light sensitivity | EASTMAN KODAK CO (US) | 2000-07-19 | — | — | CN | disclosed |
| CN-1260513-A | Pyrazolopyrrodiazole colour coupling component for photography | EASTMAN KODAK CO (US) | 2000-07-19 | — | — | CN | disclosed |
| CN-1258861-A | Photographic element containing high dye productivity colour former | EASTMAN KODAK CO (US) | 2000-07-05 | — | — | CN | disclosed |
| CN-1258021-A | Photographic material | EASTMAN KODAK CO (US) | 2000-06-28 | — | — | CN | disclosed |
| CN-1235280-A | Photographic element containing yellow dye-forming photographic coupler | EASTMAN KODAK CO (US) | 1999-11-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | MAPT 4753/4885NPC1 3512/4885SMN1; SMN2 3015/4885 |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | MAPT 2243/4885NPC1 268/4885SMN1; SMN2 3760/4885 |
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | MAPT 1811/4885NPC1 2820/4885SMN1; SMN2 3655/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | MAPT 1811/4885NPC1 2820/4885SMN1; SMN2 3655/4885 |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | MAPT 4754/4885NPC1 3891/4885SMN1; SMN2 2635/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | MAPT 4759/4885NPC1 3778/4885SMN1; SMN2 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.